Throne Science Raises $10M Series A for Gut Health AI

Throne Science has raised a $10M Series A led by Will Ventures to expand its toilet-mounted health tracking platform. Emerson Collective, Workshop, LEAD, Salt VC, Accomplice, Moxxie Ventures, and other investors also participated, according to the July 28 funding announcement. The round brings the Austin company's total funding to nearly $18M since its 2023 founding.

The financing matters because Throne is attempting to establish a new surface for continuous health data. Wrist wearables made sleep, recovery, and heart-rate trends visible by removing most of the effort from measurement. Throne applies that same passive model to stool, hydration, bathroom habits, and urinary flow, a set of daily signals that consumers and clinicians still capture through isolated snapshots, self-reporting, or not at all.

What Happened

Throne's Series A will fund three priorities: consumer education, expansion through clinical channels, and core research and development. The company has not disclosed its valuation or current growth metrics, making the commercial traction behind the round difficult to assess from the outside. What is clear is that Throne now has a broader group of investors supporting a business that combines consumer hardware, computer vision, health software, and a long-term clinical research strategy.

Will Ventures led the round, while Emerson Collective, Workshop, LEAD, Salt VC, Accomplice, and Moxxie Ventures also participated. Moxxie previously led Throne's $4M seed round announced in May 2025, which included Accomplice alongside a group of venture firms and angel investors. Crunchbase News reports nearly $18M in total funding, but the company has not publicly itemized every dollar raised between the seed and Series A announcements. The difference should not be reverse-engineered into an assumed financing round.

From Wrist Data to Bathroom Data

Throne One attaches to a toilet and uses optical and acoustic sensors to collect data during normal bathroom use. The software analyzes stool form, visit timing and regularity, hydration indicators, and urinary flow before presenting trends in the Throne app. The company's product materials position the device as a general wellness product that operates in the background, supports multiple household users, and turns a routine daily activity into a longitudinal health record.

That longitudinal record is the strategic foundation of the company. A single measurement captures one moment. Repeated passive measurements can reveal personal baselines and meaningful changes over time. For people managing digestive conditions, that could make conversations with clinicians more informed, although the device does not replace medical evaluation. For researchers, the larger opportunity is a more consistent dataset than patient recall or occasional laboratory snapshots can provide.

The Technology and Its Boundary

Throne told Crunchbase News that its computer vision pipeline uses a dozen models, some trained by practicing gastroenterologists. The company also introduced a beta Gut Health Coach that combines daily readings with user-reported information such as diet, sleep, and stress before identifying patterns associated with better or worse days. Throne's own science overview says its stool-form analysis has been tested against five board-certified gastroenterologists, while validation studies involving researchers at Harvard, Stanford, and the University of Chicago are underway.

Those results are promising, but the medical boundary remains important. Throne is a general wellness product, not a diagnostic medical device, and the company's current disclaimer states that it is not intended to diagnose, treat, cure, or prevent disease. Its longer-term vision is to identify changes that could become early warning signals for colorectal, bladder, and kidney cancers. The company's "smoke detector for colon cancer" concept remains under development and is not a capability of the product currently available.

Why the Investor Mix Matters

The investor group spans consumer technology, healthcare, sports, and mission-driven capital. Will Ventures describes itself as an investor in category-defining businesses across sports, entertainment, and consumer markets, while LEAD focuses on sports and health. Returning investors such as Moxxie and Accomplice provide continuity from Throne's seed stage, and Emerson Collective broadens the syndicate beyond traditional consumer-device investors.

That mix reflects the operational challenge Throne must solve. A toilet-mounted sensor must earn an unusually high level of trust around privacy, reliability, and the handling of deeply personal data. It also has to make an unfamiliar product category understandable without drifting into unsupported medical claims. The Series A is therefore funding more than manufacturing or customer acquisition. It is financing the education, validation, and distribution work required to make passive bathroom monitoring feel routine.

The Founding Team and Market Position

CEO Scott Hickle and CTO Timothy Blumberg began exploring smart-toilet technology before formally founding Throne in 2023. John Capodilupo, Co-Founder and CPO, previously spent a decade as WHOOP's co-founder and CTO and has written about living with ulcerative colitis. Throne's company story connects the product to that combination of engineering experience, wearable technology expertise, and firsthand experience with digestive disease.

The competitive landscape is beginning to take shape. Kohler has introduced Dekoda, another toilet-mounted health tracker, while established wearable companies have conditioned consumers to expect continuous personal data from devices that fade into the background. Throne argues that its software, battery performance, and integrated hardware experience differentiate the platform, but the market remains early and the company has not shared enough commercial data to establish a durable lead. The more measured conclusion is that both consumer technology companies and venture investors increasingly view the bathroom as a credible next frontier for health sensing.

What This Series A Signals

Throne's Series A reflects a broader shift from occasional health measurements toward passive, high-frequency monitoring. The important change is not simply placing another sensor inside the home. It is creating a continuous history of health data that can help users recognize patterns, provide researchers with denser observations, and potentially support future clinical tools following the necessary validation and regulatory work.

The next challenge is execution. Throne must demonstrate that consumers will accept a camera-based device in one of the most private spaces in the home, that its insights remain valuable after the novelty fades, and that clinical partners recognize the platform's value without confusing wellness insights with medical diagnosis. If the company can clear those hurdles, this Series A may ultimately look less like funding for an unusual consumer device and more like an early investment in a new category of ambient health infrastructure.